Jasper Therapeutics to Present at 46th Annual TD Cowen Healthcare Conference
Rhea-AI Summary
Jasper Therapeutics (Nasdaq: JSPR) announced management will present at the 46th Annual TD Cowen Healthcare Conference in Boston, March 2-4, 2026.
The company will participate in a Fireside Chat on Monday, March 2, 2026 at 3:50 PM ET. According to the company, a live webcast will be available on its investor website and an archived replay will remain online for 30 days.
Positive
- None.
Negative
- None.
News Market Reaction – JSPR
On the day this news was published, JSPR gained 1.45%, reflecting a mild positive market reaction.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Market Reality Check
Peers on Argus
Peer moves were mixed, with KLTO up 3.37%, LTRN up 0.78%, LVTX down 3.87%, and others flat. No peers appeared in the momentum scanner, pointing to stock-specific factors rather than a sector-wide move.
Historical Context
| Date | Event | Sentiment | Move | Catalyst |
|---|---|---|---|---|
| Jan 08 | CSU data update | Positive | -19.0% | Updated BEACON and OLE CSU data showing strong UAS7 improvements and safety. |
| Jan 07 | Leadership change | Positive | +7.9% | Appointment of Jeet Mahal as CEO to lead briquilimab registrational plans. |
| Dec 02 | Asthma data, probe | Positive | -8.1% | Positive ETESIAN asthma data and BEACON investigation finding no drug product issues. |
| Dec 01 | Investor webinar | Neutral | -6.5% | Announcement of webinar to present ETESIAN and BEACON investigation findings. |
| Nov 10 | Q3 2025 results | Neutral | +0.0% | Quarterly results with $50.9M cash, losses, and focus on briquilimab urticaria program. |
Positive clinical updates have previously been met with negative price reactions, while leadership and corporate updates saw more mixed responses.
Over the past several months, Jasper highlighted briquilimab’s potential in CSU and asthma with multiple positive data updates on Dec 2, 2025 and Jan 8, 2026, yet shares fell 8.14% and 19.02% after those respective releases. A CEO transition and growth focus on Jan 7, 2026 coincided with a 7.89% gain. Earlier, Q3 2025 results on Nov 10, 2025 showed ongoing losses but a cash runway extended through H1 2026. Today’s conference appearance continues this communication-heavy trajectory without adding new data.
Market Pulse Summary
This announcement highlights Jasper’s upcoming fireside chat at the TD Cowen Healthcare Conference on March 2, 2026, offering additional visibility into its briquilimab program in mast cell–driven urticaria and asthma. Recent history includes positive clinical data alongside continued losses and a cash runway into H1 2026. Investors following this story may focus on future trial milestones, updated financials, and any strategic shifts communicated during or after the event.
Key Terms
mast cell medical
chronic spontaneous urticaria (CSU) medical
chronic inducible urticaria (CIndU) medical
AI-generated analysis. Not financial advice.
REDWOOD CITY, Calif., Feb. 24, 2026 (GLOBE NEWSWIRE) -- Jasper Therapeutics, Inc. (Nasdaq: JSPR) (Jasper), a clinical stage biotechnology company focused on development of briquilimab, a novel antibody therapy targeting KIT (CD117) to address mast cell driven diseases such as chronic spontaneous urticaria (CSU), chronic inducible urticaria (CIndU) and asthma, today announced that management will participate at the 46th Annual TD Cowen Healthcare Conference, taking place March 2-4, 2026 in Boston, MA.
46th Annual TD Cowen Healthcare Conference
Conference Dates: March 2-4, 2026
Presentation Date/Time: Monday, March 2, 2026; 3:50 PM EST
Presentation Format: Fireside Chat
A live webcast of the fireside chat will be available on the News & Events – Events page of Jasper's Investor Relations website. An archived replay will be available on Jasper's website for 30 days following the live broadcast.
About Jasper
Jasper is a clinical-stage biotechnology company focused on developing briquilimab as a therapeutic for chronic mast cell diseases. Briquilimab is a targeted aglycosylated monoclonal antibody that blocks stem cell factor from binding to the cell-surface receptor KIT, thereby inhibiting signaling through the receptor. This inhibition disrupts the critical survival signal, leading to the depletion of the mast cells via apoptosis which removes the underlying source of the inflammatory response in mast cell driven diseases such as chronic urticaria and asthma. Jasper is currently conducting clinical studies of briquilimab as a treatment in patients with CSU, CIndU and asthma. Briquilimab has a demonstrated efficacy and safety profile in patients and healthy volunteers, with positive clinical outcomes in CSU, CIndU and allergic asthma. For more information, please visit us at www.jaspertx.com.
Forward-Looking Statements
Certain statements included in this press release that are not historical facts are forward-looking statements for purposes of the safe harbor provisions under the United States Private Securities Litigation Reform Act of 1995. Forward-looking statements are sometimes accompanied by words such as “believe,” “may,” “will,” “estimate,” “continue,” “anticipate,” “intend,” “expect,” “should,” “would,” “plan,” “predict,” “potential,” “seem,” “seek,” “future,” “outlook” and similar expressions that predict or indicate future events or trends or that are not statements of historical matters. These forward-looking statements include, but are not limited to, statements regarding briquilimab’s potential, including with respect to its potential in mast cell driven diseases such as CSU, CIndU and asthma; and Jasper’s participation in the 46th Annual TD Cowen Healthcare Conference. These statements are based on various assumptions, whether or not identified in this press release, and on the current expectations of Jasper and are not predictions of actual performance. These forward-looking statements are provided for illustrative purposes only and are not intended to serve as, and must not be relied on by an investor as, a guarantee, an assurance, a prediction or a definitive statement of fact or probability. Many actual events and circumstances are beyond the control of Jasper. These forward-looking statements are subject to a number of risks and uncertainties, including general economic, political and business conditions; the risk that the potential product candidates that Jasper develops may not progress through clinical development or receive required regulatory approvals within expected timelines or at all; the risk that clinical trials may not confirm any safety, potency or other product characteristics described or assumed in this press release; the risk that prior test, study and trial results may not be replicated in continuing or future studies and trials; the risk that Jasper may be unable to raise capital to continue its operations and continue the BEACON study; the risk that Jasper will be unable to successfully market or gain market acceptance of its product candidates; the risk that prior study results may not be replicated; the risk that Jasper’s product candidates may not be beneficial to patients or successfully commercialized; patients’ willingness to try new therapies and the willingness of physicians to prescribe these therapies; the effects of competition on Jasper’s business; the risk that third parties on which Jasper depends for laboratory, clinical development, manufacturing and other critical services will fail to perform satisfactorily; the risk that Jasper’s business, operations, clinical development plans and timelines, and supply chain could be adversely affected by the effects of health epidemics; the risk that Jasper will be unable to obtain and maintain sufficient intellectual property protection for its investigational products or will infringe the intellectual property protection of others; and other risks and uncertainties indicated from time to time in Jasper’s filings with the SEC, including its Annual Report on Form 10-K for the year ended December 31, 2024 and subsequent Quarterly Reports on Form 10-Q. If any of these risks materialize or Jasper’s assumptions prove incorrect, actual results could differ materially from the results implied by these forward-looking statements. While Jasper may elect to update these forward-looking statements at some point in the future, Jasper specifically disclaims any obligation to do so. These forward-looking statements should not be relied upon as representing Jasper’s assessments of any date subsequent to the date of this press release. Accordingly, undue reliance should not be placed upon the forward-looking statements.
Contacts:
Alex Gray (investors)
Jasper Therapeutics
650-549-1454
agray@jaspertx.com
Joyce Allaire (investors)
LifeSci Advisors
617-435-6602
jallaire@lifesciadvisors.com
Media:
media@jaspertx.com
FAQ
When will Jasper Therapeutics (JSPR) present at the TD Cowen Healthcare Conference?
How can investors watch Jasper Therapeutics (JSPR) at the March 2026 TD Cowen conference?
What topics will Jasper Therapeutics (JSPR) likely cover in the March 2, 2026 fireside chat?
Where and when is the 46th Annual TD Cowen Healthcare Conference that Jasper (JSPR) will attend?
Will Jasper Therapeutics (JSPR) provide a replay of their March 2, 2026 presentation?
